Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anke Kretz-Rommel

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Expert Opinion on Biological Therapy|December 18, 2007
Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppressionAnke Kretz-Rommel, Katherine S Bowdish
Biochemical Pharmacology|September 15, 2012
Opportunities for functional selectivity in GPCR antibodiesDavid R Webb, Tracy M Handel, Anke Kretz-Rommel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2008
Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapyAnke Kretz-Rommel, Fenghua Qin, Naveen Dakappagari, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 26, 2007
In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse modelsAnke Kretz-Rommel, Fenghua Qin, Naveen Dakappagari, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 26, 2007
In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate modelCândida F Pereira, Ruurd Torensma, Konnie Hebeda, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 21, 2005
Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responsesNaveen Dakappagari, Toshiaki Maruyama, Mark Renshaw, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2006
Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulationJohn R McWhirter, Anke Kretz-Rommel, Alan Saven, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2008
No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentationPaul J Tacken, Ben Joosten, Anita Reddy, et al.
Molecular Cancer Therapeutics|July 18, 2012
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexesJoshua E Allen, Roger Ferrini, David T Dicker, et al.
The Journal of Biological Chemistry|April 30, 2016
Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) AntibodiesChristophe Blanchetot, Natalie De Jonge, Aline Desmyter, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Expert Opinion on Biological Therapy|December 18, 2007
Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppressionAnke Kretz-Rommel, Katherine S Bowdish
Biochemical Pharmacology|September 15, 2012
Opportunities for functional selectivity in GPCR antibodiesDavid R Webb, Tracy M Handel, Anke Kretz-Rommel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2008
Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapyAnke Kretz-Rommel, Fenghua Qin, Naveen Dakappagari, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 26, 2007
In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse modelsAnke Kretz-Rommel, Fenghua Qin, Naveen Dakappagari, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 26, 2007
In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate modelCândida F Pereira, Ruurd Torensma, Konnie Hebeda, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 21, 2005
Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responsesNaveen Dakappagari, Toshiaki Maruyama, Mark Renshaw, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2006
Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulationJohn R McWhirter, Anke Kretz-Rommel, Alan Saven, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2008
No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentationPaul J Tacken, Ben Joosten, Anita Reddy, et al.
Molecular Cancer Therapeutics|July 18, 2012
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexesJoshua E Allen, Roger Ferrini, David T Dicker, et al.
The Journal of Biological Chemistry|April 30, 2016
Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) AntibodiesChristophe Blanchetot, Natalie De Jonge, Aline Desmyter, et al.
Pageof 2